COPD Screening Without Symptoms: a Grade D Built on Zero Trials

Someone who has smoked for twenty years runs the arithmetic eventually, and it tends to happen late, alone, with a phone in hand. Chronic lower respiratory disease, which is mostly chronic obstructive pulmonary disease, is the sixth leading cause of death in the United States, and roughly 6% of American adults had been diagnosed with COPD as of 2020. A test exists. It is inexpensive, it takes a few minutes, and it consists of blowing hard into a tube. Asking for one seems like the least a person could do.

The answer that comes back is frequently a flat no, delivered briskly and with very little showing of the work. The reasoning behind that no is public and quite specific, and it is considerably narrower than the refusal tends to sound. Narrow enough, in fact, that a good share of the people who go looking for it will find the recommendation was never about them.

In May 2022 the US Preventive Services Task Force published a reaffirmation recommendation statement in JAMA, updating a position it first took in 2016. A reaffirmation is a deliberately narrow instrument. Rather than rebuilding an evidence base from the foundations, the Task Force commissions a targeted update aimed at a few key questions and asks whether anything has moved. The commissioned review, by Elizabeth M. Webber, Jennifer S. Lin and Rachel G. Thomas, searched MEDLINE, the Cochrane Central Register of Controlled Trials and CINAHL for studies published between 1 January 2015 and 22 January 2021, with surveillance running through 25 March 2022.

Two inclusion criteria shape how the result should be read. Screening studies had to be conducted in people who do not recognise or report respiratory symptoms. Treatment studies had to be in people with mild or moderate, or minimally symptomatic, COPD, which is the population a screening programme would actually surface rather than the sicker patients who arrive at a clinic under their own steam. Two reviewers appraised each article independently, and the review states plainly that no quantitative synthesis was conducted, so its findings are narrated rather than pooled into a single summary estimate.

The central result is a number, and the number is zero. The review included no trials on the effectiveness of screening. On the question of whether testing the lungs of adults who report no symptoms improves morbidity, mortality or health-related quality of life, the Task Force found no studies that directly assess it. Not studies with disappointing results. No studies.

Evidence about treatment did exist, and it was reasonably solid. Three trials or analyses covering 20,058 people addressed drug treatment, and the reduction in the annual rate of moderate to severe exacerbations reached 29% (95% CI, 22% to 35%) for a long-acting beta agonist combined with an inhaled corticosteroid. Thirteen trials covering 3,657 people tested non-drug interventions, and there the review found no consistent benefit across a range of patient outcomes. The catch is provenance: the treatment evidence remains largely limited to people with moderate airflow obstruction, which is precisely not the group a screening programme is designed to find.

Harms were not hypothetical either. Two large observational studies covering 243,517 people in a screen-relevant population associated the initiation of a long-acting muscarinic antagonist or a long-acting beta agonist in treatment-naive patients with serious cardiovascular events, at adjusted odds ratios of 1.50 (95% CI, 1.35 to 1.67) and 1.52 (95% CI, 1.28 to 1.80) for the two drug classes, and associated inhaled corticosteroid use with developing diabetes. These are observational associations rather than randomised findings, and the Task Force weighs them as such.

The screening instruments carry a quieter problem. Across externally validated questionnaires, sensitivity ranged from 67% to 90% and specificity ranged from 25% to 73%. Specificity of 25% means that at the weak end of that range, three of every four people without COPD are flagged as possibly having it, and each of those flags becomes a spirometry referral, a wait and a conversation. Set alongside a treatment benefit demonstrated mostly in a sicker population and a harm signal concentrated in the treatment-naive, the Task Force concluded with moderate certainty that screening asymptomatic adults produces no net benefit, and issued a D, its grade for a service whose harms it judges to outweigh its benefits.

The recommendation governs one population: asymptomatic adults who do not recognise or report respiratory symptoms. It explicitly does not reach anyone with chronic cough, sputum production, difficulty breathing or wheezing. It does not reach people at very high risk, such as those with alpha-1 antitrypsin deficiency. It does not reach workers with known occupational exposures.

That list does an enormous amount of work, and it is usually the part lost in the retelling. A person who has given up the stairs, or who no longer walks the hill on the way home, or who has quietly rebuilt a daily routine around not becoming breathless, is not obviously inside the population a D grade covers. The Task Force's own phrasing concedes the seam. The population is defined as people who do not recognise or report symptoms, and that is a category assembled from what someone thinks to mention during a ten-minute appointment, not from what their lungs are doing.

It would be easy to read the D as the Task Force declaring that early COPD does not matter, and the document says nothing of the kind. It says that a chain of reasoning, running from screen to find to treat to a longer or better life, has never been tested end to end in this population, and that the individual links which have been tested were tested in different people. A recommendation against screening is often a statement about the state of the evidence rather than about the state of the disease, and this one wears that on its face.

There is a version of this finding that reads as a research agenda rather than as clinical guidance, because the trial could be run and has not been. Until it is, the honest reading is that the recommendation rests on an absence, that the absence has stood since at least 2016, and that a literature search closing in March 2022 cannot speak to anything published after it. What the document does explain is why the exchange in the examination room goes the way it does, and why the exclusion list, rather than the letter grade, is the part that determines who the recommendation applies to at all.

The D grade reads as a dismissal and is closer to an admission. Stated plainly, the Task Force is reporting that nobody has run the trial: after decades of a disease that sits sixth on the list of what kills Americans, the question of whether finding it early in people who feel fine does them any good has not been asked in a form capable of answering it. That is a gap in the research agenda arriving in patients' hands dressed as guidance, and the two are not the same object. The recommendation is also far narrower than its reputation, since it dissolves the moment a symptom is on the table, and asymptomatic here is a category built from what a person thinks to mention rather than from a measurement. The most useful passage in the whole document may be the exclusion list, which is where a substantial share of the people genuinely worried about their lungs will find themselves standing.